Twist Bioscience maintains a conservative capital structure characterized by zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet reflects total assets of $641.9 million against…
Urogen Pharma Ltd presents a capital structure characterized by negative total equity of -105.47 million USD, driven by total liabilities of 305.93 million USD exceeding total assets of 200.46 mill…
The company maintains a conservative capital structure with a debt-to-equity ratio of 0.32, indicating limited leverage relative to shareholder equity. Total liabilities stand at $433.8 million aga…
Veracyte maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet is heavily weighted toward equity, with total equity of $1.31 billi…
GeneDx Holdings Corp maintains a conservative capital structure with a debt-to-equity ratio of 0.16, indicating limited leverage relative to its equity base of $308.2 million. The company holds $10…
Heartbeam Inc maintains a debt-free capital structure with a debt-to-equity ratio of 0.0, supported by cash and equivalents of $4.38 million against total liabilities of $3.24 million. The company’…
Medtronic PLC maintains a conservative capital structure with a reported debt-to-equity ratio of 0.0, indicating minimal leverage relative to its equity base of $49.46 billion. The company holds $1…
Koninklijke Philips NV maintains a capital structure characterized by significant leverage, with long-term debt of €7.81 billion against total equity of €10.96 billion, resulting in a debt-to-equit…
Stryker maintains a capital structure characterized by significant leverage, with long-term debt of $14.86 billion against total equity of $22.42 billion, resulting in a debt-to-equity ratio of 0.6…
Bio-Techne Corp maintains a conservative capital structure characterized by zero debt and a debt-to-equity ratio of 0.0. The company holds $162.2 million in cash and equivalents against total asset…
Japan Tobacco Inc maintains a balanced capital structure with a debt-to-equity ratio of 0.41 and a current ratio of 1.93, indicating adequate short-term liquidity despite a medium liquidity risk as…
Abbott Laboratories maintains a conservative capital structure with a debt-to-equity ratio of 0.19, indicating low leverage relative to its equity base of $52.13 billion. The company holds $8.52 bi…
Alkermes maintains a conservative capital structure characterized by zero reported debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet reflects total assets of $2.49 billion against…
The company exhibits a distressed capital structure with negative total equity of -$8.3 million and total liabilities of $42.8 million exceeding total assets of $34.4 million. Long-term debt stands…
Assembly Biosciences maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet holds $58.45 million in cash and equivalents against to…
Biogen maintains a conservative capital structure with a debt-to-equity ratio of 0.34, indicating limited leverage relative to shareholder equity. The balance sheet shows total assets of $29.44 bil…
Genmab maintains a capital structure characterized by significant leverage, with long-term debt of $5.43 billion against total equity of $5.85 billion, resulting in a debt-to-equity ratio of 0.93.…
Genius Group Ltd operates with a market price of $0.2633 per share, but no liquidity metrics or capital structure details are available for analysis. The company's valuation snapshot lacks sufficie…
Haemonetics maintains a capital structure characterized by significant leverage, with long-term debt of $1.22 billion against total equity of $796.3 million, resulting in a debt-to-equity ratio of…
The company maintains a debt-free capital structure with a debt-to-equity ratio of 0.0, supported by cash and equivalents of $236.0 million against total assets of $1.02 billion. Despite holding si…
The company maintains a conservative capital structure with zero debt-to-equity ratio and total liabilities of $27.8 million against total assets of $512.4 million. Total equity stands at $484.7 mi…
Sarepta Therapeutics maintains a capital structure characterized by significant leverage relative to its equity base, with a debt-to-equity ratio of 0.73. The company holds $801.3 million in cash a…
Vericel Corp maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet holds $100.1 million in cash and equivalents against total liab…
Meiji Holdings maintains a conservative capital structure with a debt-to-equity ratio of 0.15 and a current ratio of 1.87, indicating adequate short-term liquidity coverage. The company holds JPY 6…
Takeda maintains a capital structure characterized by significant leverage, with long-term debt of 4.88 trillion JPY against total equity of 7.43 trillion JPY, resulting in a debt-to-equity ratio o…
(a) Capital structure and liquidity are characterized by a debt-free balance sheet, with a debt-to-equity ratio of 0.0. The company holds total assets of $1.39 billion against total equity of $466.…
Tipharco Pharmaceutical JSC maintains a conservative capital structure with a debt-to-equity ratio of 0.19 and a current ratio of 2.29, indicating strong short-term liquidity coverage. The company…
Johnson & Johnson maintains a substantial balance sheet with total assets of $199.2 billion and total equity of $81.5 billion. The company carries $39.4 billion in long-term debt against $19.7 bill…
Kymera Therapeutics maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet shows total assets of $1.74 billion against total liabil…
Thermo Fisher Scientific maintains a substantial asset base of $110.3 billion, supported by total equity of $53.4 billion and long-term debt of $39.2 billion. The company holds $9.9 billion in cash…
Agilent Technologies maintains a balanced capital structure with total assets of $12.73 billion and total liabilities of $5.99 billion, resulting in total equity of $6.74 billion. The company holds…
Humm Group Ltd maintains a highly leveraged capital structure, with total liabilities of 4.84 billion AUD against total equity of 503.2 million AUD, resulting in a debt-to-equity ratio of 9.3. The…
Humana maintains a capital structure characterized by significant leverage, with long-term debt of $12.37 billion against total equity of $17.66 billion, resulting in a debt-to-equity ratio of 0.70…
Personalis maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The balance sheet holds $124.2 million in cash and equivalents against total assets…
GC Biopharma Corp has a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing, and a current ratio of 1.55, suggesting it has sufficient short-term assets to cover its liab…
Sihuan Pharmaceutical Holdings Group Ltd has a market capitalization of CNY 9.33 billion and a price-to-earnings ratio of 51.91, indicating a relatively high valuation compared to its earnings. The…
Cspc Pharmaceutical Group Ltd maintains a strong liquidity position with a current ratio of 2.19, indicating the company can cover its short-term liabilities more than twice over. The company's liq…
Astra Industrial Group Company SJSC maintains a conservative capital structure with a debt-to-equity ratio of 0.08, indicating minimal leverage relative to its equity base of 2.96 billion SAR. The…
Accuray Inc has a market capitalization of $33.83 million and a price-to-book ratio of 0.42, indicating a significant discount to its book value. The company's liquidity position is characterized b…
Avalo Therapeutics Inc has a market capitalization of $999.27 million and a price-to-earnings ratio of 10.15, indicating a relatively low valuation compared to earnings. The company's liquidity pos…
Aytu Biopharma Inc has a market price of $2.27, with a market capitalization of $24.36 million, and a price-to-book ratio of 0.79, indicating that the company is trading at a discount to its book v…
BNB Plus Corp maintains a debt-free capital structure with a debt-to-equity ratio of 0.0, supported by total equity of $2.3 million and cash and equivalents of $1.7 million against total liabilitie…
DiaMedica Therapeutics Inc operates with a market capitalization of $342.7 million and a price-to-book ratio of 6.42, indicating a premium valuation relative to its book value. The company's liquid…
Alpha Tau Medical Ltd maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds $12.2 million in cash and equivalents against total as…
electroCore operates with a negative equity position of -$1.71 million and a cash balance of $7.04 million, indicating a liquidity cushion that covers 107% of its $6.61 million long-term debt. The…
EW.PS maintains a capital structure characterized by significant leverage relative to its equity base, with total liabilities of PHP 495.6 billion against total equity of PHP 81.5 billion. The debt…
The company maintains a conservative capital structure with zero debt-to-equity and total liabilities of $23.85 million against total equity of $106.03 million. Liquidity is supported by cash and e…
Heron Therapeutics operates with a high debt-to-equity ratio of 9.81, indicating a capital structure heavily reliant on debt financing. The company's liquidity position is characterized by a curren…
Inovio Pharmaceuticals Inc operates with a market capitalization of $110.84 million and a price-to-book ratio of 1.17, indicating a relatively modest premium over its book value. The company's liqu…
Kossan Rubber Industries Bhd maintains a strong liquidity position, with a current ratio of 9.78, indicating that the company holds significantly more current assets than current liabilities. The c…
Eli Lilly and Co maintains a capital structure with a debt-to-equity ratio of 2.05, indicating a significant reliance on debt financing. The company's liquidity position is characterized as medium,…
Larimar Therapeutics operates with a strong liquidity position, as evidenced by its cash and equivalents of $85.4 million, which significantly exceeds its total liabilities of $67.8 million, result…
Max Healthcare Institute Ltd maintains a strong liquidity position, with a current ratio of 1.37, indicating the company can cover its short-term liabilities with its short-term assets. The company…
Medartis Holding AG maintains a debt-to-equity ratio of 0.69 and a current ratio of 2.21, indicating a moderate level of leverage and strong short-term liquidity. The company's liquidity position i…
Mesoblast maintains a conservative capital structure with a debt-to-equity ratio of 0.21 and a current ratio of 1.99, indicating adequate short-term liquidity coverage. The company holds total asse…
MacroGenics Inc has a market capitalization of $269.5 million and a price-to-book ratio of 4.85, indicating that the market is valuing the company at a premium to its book value. The company's liqu…
Medacta Group SA maintains a balanced capital structure with a debt-to-equity ratio of 0.57 and a current ratio of 2.08, indicating adequate short-term liquidity despite a medium liquidity risk rat…
NewAmsterdam Pharma Company NV maintains a conservative capital structure characterized by zero debt and substantial liquidity reserves. The balance sheet reports total assets of $769.3 million, wi…
Omnicell Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.0, indicating no reported interest-bearing debt relative to equity. The company holds $196.52 million in cas…
Omada Health maintains a robust liquidity position with $222.0 million in cash and equivalents against total liabilities of $75.7 million. The balance sheet is debt-free, with long-term debt at $0.…
PAVmed operates with a market capitalization of $46.91 million and a price-to-earnings ratio of 116.98, indicating a high valuation relative to its earnings. The company's liquidity position is con…
PDS Biotechnology Corp maintains a strong liquidity position, with $57.7 million in cash and equivalents, significantly exceeding its total liabilities of $29.6 million, resulting in a current rati…
Pfizer Inc maintains a capital structure characterized by significant leverage, with long-term debt of $61.64 billion against total equity of $86.48 billion, resulting in a debt-to-equity ratio of…
Piramal Pharma Ltd maintains a capital structure characterized by significant leverage, with long-term debt of INR 56.7 billion against total equity of INR 81.6 billion, resulting in a debt-to-equi…
Palvella Therapeutics Inc maintains a strong liquidity position, with cash and equivalents of $57.98 million, significantly exceeding its total liabilities of $31.58 million, resulting in a current…
RDY.AX has a liquidity ratio of 0.81, indicating that its current assets are less than its current liabilities, which suggests potential short-term liquidity challenges. The company's debt-to-equit…
Regenxbio Inc operates with a capital structure that includes a debt-to-equity ratio of 1.82, indicating a relatively high reliance on debt financing. The company's liquidity position is characteri…
Rhoen Klinikum AG maintains a conservative capital structure with a debt-to-equity ratio of 0.09, significantly below the industry median, indicating a low reliance on debt financing. The company's…
Rezolute Inc maintains a strong liquidity position, with a current ratio of 13.39, indicating that the company has significantly more current assets than current liabilities. The company's cash and…
Sana Biotechnology Inc has a market capitalization of $863.85 million and a price-to-book ratio of 5.37, indicating a premium valuation relative to its book value. The company's liquidity position…
Sagimet Biosciences Inc maintains a strong liquidity position, with a current ratio of 29.11 and cash and equivalents of $95.96 million, which significantly exceeds its total liabilities of $5.73 m…
Sensei Biotherapeutics maintains a strong liquidity position with a current ratio of 12.07, indicating that its current assets significantly exceed its current liabilities. The company's cash and e…
Sutro Biopharma Inc operates with a negative equity position of -$132.45 million and a cash and equivalents balance of $58.13 million, indicating a liquidity position that is constrained by its neg…
Shattuck Labs Inc has a strong liquidity position, with a current ratio of 11.7 and $54.2 million in cash and equivalents, indicating a robust ability to meet short-term obligations. The company ha…
Tilray Brands Inc has a liquidity position that is currently medium, with a current ratio of 2.46 and a negative free cash flow of -$2.08 billion. The company's cash and equivalents stand at $221.6…
Trevi Therapeutics maintains a conservative capital structure with zero debt, resulting in a debt-to-equity ratio of 0.0. The company holds $189.1 million in cash and equivalents against total asse…
Vistagen Therapeutics Inc operates with a highly liquid capital structure, as evidenced by its cash and equivalents of $119.17 million, which significantly exceeds its total liabilities of $9.37 mi…
Whitehawk Therapeutics operates with a strong liquidity position, as evidenced by its cash and equivalents of $37.57 million and a current ratio of 10.26, indicating a robust ability to meet short-…
Xenon Pharmaceuticals maintains a robust balance sheet characterized by zero debt and substantial liquidity. The company holds $199.2 million in cash and equivalents against total liabilities of $5…
Zealand Pharma maintains a highly conservative capital structure characterized by minimal leverage and substantial liquidity. The company reports a debt-to-equity ratio of 0.03, indicating negligib…
Zura Bio maintains a strong liquidity position, with a current ratio of 9.05 and cash and equivalents of $109.41 million, which significantly exceeds its total liabilities of $12.41 million. The co…
Dezhan Healthcare maintains a strong liquidity position, as evidenced by a current ratio of 34.87, indicating that the company has significantly more current assets than current liabilities. Howeve…
Guangdong Zhongsheng Pharmaceutical Co Ltd maintains a strong liquidity position, as evidenced by a current ratio of 4.24, indicating that the company has sufficient current assets to cover its cur…
Taisei Corp maintains a conservative capital structure with a debt-to-equity ratio of 0.49 and a current ratio of 1.19. The balance sheet shows total assets of JPY 2.71 trillion against total liabi…
SSY Group Ltd maintains a debt-to-equity ratio of 0.55, indicating a moderate reliance on debt financing, and a current ratio of 1.89, suggesting adequate short-term liquidity to meet obligations.…
Aldeyra Therapeutics Inc has a market capitalization of $100.13 million and a price-to-book ratio of 1.02, indicating that the market value is closely aligned with the company's book value. The com…
Boundless Bio maintains a strong liquidity position with a current ratio of 20.45, indicating that its current assets significantly exceed its current liabilities. The company's cash and equivalent…
Genus PLC maintains a capital structure characterized by significant leverage relative to equity, with a debt-to-equity ratio of 0.56 and long-term debt totaling £265.9 million against total equity…
Kalaris Therapeutics Inc maintains a strong liquidity position, with a current ratio of 18.48 and $86.04 million in cash and equivalents, indicating a robust ability to meet short-term obligations.…
Kiniksa Pharmaceuticals maintains a strong liquidity position, with $165.6 million in cash and equivalents and no long-term debt, resulting in a debt-to-equity ratio of 0.0. The company's current r…
Lupin Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.2, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, wi…
Maravai LifeSciences has a market capitalization of $1.12 billion and a price-to-book ratio of 5.29, indicating a premium valuation relative to its book value. The company's liquidity position is c…
Phibro Animal Health Corp maintains a capital structure with a debt-to-equity ratio of 2.52, indicating a relatively high reliance on debt financing. The company's liquidity position is characteriz…
Passage Bio Inc operates with a highly liquid capital structure, as evidenced by a current ratio of 8.43 and a cash and equivalents balance of $36.77 million, which significantly exceeds its total…
Structure and Liquidity Prothena maintains a strong liquidity position with $307.5 million in cash and equivalents, representing 94% of its total assets of $326.8 million. The company has no long-t…
Rallybio Corp has a market capitalization of $75.17 million and a price-to-book ratio of 0.84, indicating that the company is trading at a discount relative to its book value. The company's liquidi…
Structure and Liquidity Soleno Therapeutics Inc maintains a strong liquidity position, with a current ratio of 5.8, indicating a significant buffer of current assets over current liabilities. The c…
SNDL Inc's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage profile. The company maintains a strong liquidity position with a current rat…
Strongpoint ASA has a market capitalization of NOK 1.37 billion and a price-to-book ratio of 3.03, indicating a premium valuation relative to its book value. The company's liquidity position is cha…
Protara Therapeutics Inc maintains a strong liquidity position, with a current ratio of 16.33 and cash and equivalents of $89.58 million, which significantly exceeds its total liabilities of $9.60…
Tenaya Therapeutics Inc maintains a strong liquidity position, with a current ratio of 6.28 and $58.13 million in cash and equivalents, indicating a robust short-term financial buffer. The company…
Lotus Pharmaceutical Co Ltd has a debt-to-equity ratio of 2.35, indicating a capital structure that is significantly leveraged. The company's liquidity position is characterized by a current ratio…
Alteogen Inc maintains a strong liquidity position, with a current ratio of 2.01 and free cash flow of 117,245,087,620 KRW, indicating the company's ability to meet short-term obligations and fund…
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 12.18, indicating a high ability to meet short-term obligations. The company's liquidity FPT…
Structure and Liquidity AbbVie has a high debt-to-equity ratio of 9.24, indicating a capital structure heavily reliant on debt financing. The company's cash and equivalents of $18.07 billion are in…
AMED.O maintains a conservative capital structure with a debt-to-equity ratio of 0.33 and a current ratio of 1.23, indicating adequate short-term liquidity despite a medium liquidity risk assessmen…
Delcath maintains a strong liquidity position with $43.45 million in cash and equivalents, representing 35.1% of total assets, and a current ratio of 10.92, indicating robust short-term financial h…
Fortress Biotech Inc has a liquidity position that is relatively strong, with cash and equivalents amounting to $79.38 million, which is significantly higher than its short-term liabilities. The co…
IDEXX Laboratories Inc maintains a capital structure with a debt-to-equity ratio of 0.6, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a cur…
Immix Biopharma maintains a strong liquidity position with $93.9 million in cash and equivalents against total liabilities of $11.0 million, resulting in a debt-to-equity ratio of 0.0. The company…
INmune Bio Inc has a market capitalization of $44.66 million and a price-to-book ratio of 1.54, indicating that the market values the company at a premium to its book value. The company's liquidity…
Intervacc AB operates with a capital structure that is predominantly equity-funded, as evidenced by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's liquidity…
Kuros Biosciences AG maintains a conservative capital structure with a debt-to-equity ratio of 0.06, indicating minimal leverage and a strong equity base. The company's liquidity position is charac…
Lantheus Holdings Inc has a market capitalization of $6.14 billion and a price-to-earnings ratio of 26.29, which is above the industry median for medical equipment and supplies firms. The company's…
Mediwound operates with a market capitalization of $216.43 million and a price-to-book ratio of 4.96, indicating a premium valuation relative to its book value. The company's liquidity position is…
Natco Pharma Ltd maintains a strong liquidity position with a current ratio of 5.59, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liq…
Neumora Therapeutics maintains a strong liquidity position, with a current ratio of 17.22, indicating that the company has significantly more current assets than current liabilities. The company's…
Nuvectis Pharma Inc maintains a strong liquidity position, with cash and equivalents amounting to $31.63 million, significantly exceeding its total liabilities of $13.30 million, resulting in a cur…
Paxman AB (publ) has a market price of 11.56 SEK and a market capitalization of 269,040,688.96 SEK, indicating a moderate valuation in the healthcare equipment and supplies industry. The company's…
Pro-Dex Inc maintains a relatively strong liquidity position, with a current ratio of 3.23, indicating the company can cover its short-term liabilities more than three times over with its current a…
Profound Medical Corp has a highly liquid capital structure, with a current ratio of 12.52, indicating strong short-term liquidity. However, the company has negative operating and free cash flows,…
(a) Capital structure and liquidity: The company holds $222 million in cash and equivalents against $99 million in long-term debt, resulting in a conservative debt-to-equity ratio of 0.16. Despite…
Sanara Medtech Inc has a highly leveraged capital structure, with total liabilities of $67.0 million and total equity of $5.94 million, resulting in a debt-to-equity ratio of 7.74. The company's li…
Spero Therapeutics maintains a strong liquidity position with $63.5 million in cash and equivalents, representing 42.4% of total assets, and a current ratio of 2.68, indicating the company can cove…
Tectonic Therapeutic Inc maintains a strong liquidity position, with a current ratio of 26.63 and cash and equivalents amounting to $253.8 million, which significantly exceeds its total liabilities…
Terns Pharmaceuticals Inc has a highly liquid capital structure, with cash and equivalents amounting to $500.79 million, representing nearly half of its total assets of $1.03 billion. The company h…
Instil Bio Inc has a capital structure characterized by a debt-to-equity ratio of 0.74, indicating a moderate reliance on debt financing. The company's liquidity position is reflected in a current…
Treace Medical Concepts, Inc has a market capitalization of $179.45 million and a price-to-book ratio of 2.05, indicating that the market values the company at a premium to its book value. The comp…
ZimVie maintains a capital structure characterized by moderate leverage and adequate short-term liquidity. The company holds total assets of $753.7 million against total liabilities of $372.0 milli…
Medy Tox Inc has a market capitalization of 644.37 billion KRW and a price-to-earnings ratio of 38.83, indicating a relatively high valuation compared to its earnings. The company's price-to-book r…
The company's capital structure is characterized by a debt-to-equity ratio of 0.41, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ra…
Anhui Anke Biotechnology Group Co Ltd maintains a strong liquidity position, with a current ratio of 3.74, indicating the company can cover its short-term liabilities more than three times over. Th…
The company's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage profile. However, its liquidity position is rated as medium, with a curren…
Eisai maintains a conservative capital structure with a debt-to-equity ratio of 0.21 and a current ratio of 2.24, indicating strong short-term liquidity coverage. The balance sheet shows total asse…
Zhangzhou Pientzehuang Pharmaceutical Co Ltd maintains a strong capital structure with a debt-to-equity ratio of 0.08, indicating a low reliance on debt financing. The company's liquidity position…
Zhejiang Huahai Pharmaceutical Co Ltd maintains a capital structure characterized by significant leverage, with long-term debt of 7.48 billion CNY against total equity of 8.90 billion CNY, resultin…
Aprea Therapeutics Inc maintains a strong liquidity position, with cash and equivalents amounting to $32.37 million, significantly exceeding its total liabilities of $2.97 million, resulting in a c…
Anavex Life Sciences Corp maintains a strong liquidity position, with cash and equivalents amounting to $139.39 million, representing 96.4% of total assets. The company has no long-term debt and a…
BioMarin's capital structure is characterized by a debt-to-equity ratio of 0.21, indicating a relatively conservative leverage position. The company holds $313.9 million in cash and equivalents, bu…
DocGo Inc has a market capitalization of $58.39 million and a price-to-book ratio of 0.41, indicating a significant discount to its book value. The company's liquidity position is strong, with a cu…
Editas Medicine Inc has a market capitalization of $279.03 million and a price-to-book ratio of 1.2, indicating that the market values the company at a slight premium to its book value. The company…
Elekta’s capital structure is characterized by significant leverage and tight liquidity. The company reports total equity of SEK 7.1 billion against total liabilities of SEK 19.9 billion, resulting…
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors, relying on external financing and strategic services agreem…
Grifols SA operates in the pharmaceuticals industry, focusing on plasma-derived therapies, though specific operational details and revenue sources are not disclosed in the available data. The compa…
Humacyte operates with a negative equity position of -$28.29 million and a total asset base of $138.28 million, indicating a capital structure heavily reliant on liabilities, particularly long-term…
iBio Inc operates with a market capitalization of $56.38 million and a price-to-book ratio of 2.27, indicating a premium valuation relative to its book value. The company's liquidity position is ch…
Vi sender deg én e-post når Handelsavisen lanseres. Ingen spam, ingen annen bruk.
Ved å registrere deg samtykker du til å motta ett enkelt varsel fra Handelsavisen på lanseringsdagen.